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Previewsculmination of multiple structural studies
and provides a fresh perspective on
a critical complex in the NER process.
The proposed model also highlights the
critical requirement to study full-length
proteins and multi-protein complexes to
understand how the evolving architecture
of the NER machine, and the resulting
structural changes induced in the DNA
substrate, drive the progression of bio-
chemical steps required for repair.ACKNOWLEDGMENTS
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In this issue of Structure, Carafoli et al. investigate the mode of antibody-mediated inhibition of the discoidin
domain receptor 1 (DDR1). These studies also provide new insight into activation of the DDRs, which are
unique among receptor tyrosine kinases in the composition of their extracellular regions.Like many receptor tyrosine kinases
(RTKs) the two members of the discoidin
domain receptor family (DDR1 and
DDR2) regulate fundamental cellular
process such as proliferation, differen-
tiation and adhesion (Leitinger, 2011;
Lemmon and Schlessinger, 2010). Dysre-
gulation of these receptors is linked to
a number of human diseases, including
fibrotic disorders, atherosclerosis, and
cancer. Mounting evidence suggests
that DDRs are relevant therapeutic targets
(Valiathan et al., 2012). Inhibitory anti-
bodies, such as those described by Cara-
foli et al. (2012) in this issue of Structure,
will be critical in evaluating the potential
of DDR inhibition in disease settings.
DDRs are unusual RTKs in several
respects. DDR activators—extracellularmatrix collagens in their native triple-helical
conformation—are unique among RTK
ligands. Short triple-helical collagen-
derived peptides are sufficient to activate
DDRs, suggesting that receptor clustering
induced by collagen may not be an essen-
tial aspect of DDR activation. It is believed
that DDRs exist as preformed dimers in
cells and that collagen binding activates
signaling by altering the conformation of
these dimers, rather than by inducing
receptor oligomerization as seen for many
RTKs (Lemmon and Schlessinger, 2010).
The intracellular events following collagen-
inducedDDR activation are broadly similar
to those with other RTKs. The recep-
tors undergo autophosphorylation, recruit
signaling adaptors (including Shc and
Nck), and activate downstream signalingcascades including the mitogen-activated
protein kinase pathway. However, the
timing of these events is unusually slow
and sustained. Exactly how this relates to
signaling outcome is unclear.
A further unusual feature of DDRs is the
unique domain composition of the extra-
cellular region, of which Carafoli et al.
(2012) present the most complete picture
to date. They describe the X-ray crystal
structure of the DDR1 extracellular region
(ECR) lacking only the z50 amino acid,
presumed unstructured, juxtamembrane
(JM) region. The ECR of DDR1 contains
two discoidin (DS) domains, members of
the coagulation factor V/VIII type C super-
family. No other RTK contains extracel-
lular DS domains, but these domains are
found in a number of other proteins
A B
Figure 1. Insights from the Structure of the Extracellular Region of DDR1 Bound to an
Inhibitory Fab
(A) View of the Fab/DDR1 complex highlighting key structural features.
(B) Two possible models for collagen (red) mediated DDR1 activation. In the first, the conserved patch
(pink) is involved in inter-receptor contacts in the dimer, whereas in the second, this region is a secondary,
presumed low affinity, binding site that promotes ligand crosslinking of two receptor molecules. Linking
these events to intracelluar kinase domain activation is complicated by the presence of a long, unstruc-
tured extracellular juxtamembrane region (dashed line). Binding of mAb to the DS-like domain sterically
blocks formation of the signaling active dimer.
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Previewsinvolved in cell adhesion. Carafoli et al.
(2009) previously determined the crystal
structure of the N-terminal DS domain of
DDR2 bound to a triple-helical collagen
peptide. The DS domain has a barrel-like
fold, and collagen binds to three loops
or spikes that protrude from one of its
ends—a common site for ligand binding
to this structural family. The structure of
the DDR1 ECR now confirms that the
second globular domain also shares
structural similarity with DS domains. The
second DS-like domain has a long insert
between the first two b strands of the DS
core that augments the protrusions on
the ‘‘ligand-binding’’ end of the barrel
and contributes to an extensive interface
between the two domains. DS domains
are often found as tandem repeats, and
the relative orientation of the two domains
in DDR1 is reminiscent of that observed in
neuropilin (Vander Kooi et al., 2007).
However, the packing of the two domains
is much looser in DDR1 (surface comple-
mentarity [Sc] value of 0.56) than in neuro-
pilin (Sc value of 0.77). The looser coupling
between the two domains in DDR1
suggests that alterations in the relative
orientation of the DS and DS-like domains
upon receptor activation might be a
source of conformational rearrangement
in the DDR1 dimer.
This almost complete view of the DDR1
ECR is just one of several important
advances that were enabled by the panel
of inhibitory antibodies developed and
described by Carafoli et al. (2012). Crys-
tals of the DDR1 ECR could only be ob-tained in complex with the Fab fragment
from one of these antibodies (Figure 1A).
Antibodies were generated using re-
combinant soluble DDR1 ECR (including
the JM region), and seven were found to
inhibit collagen-induced phosphorylation
of DDR1 in cultured cells. Inhibition was
as effective with the Fab fragments from
these antibodies, indicating that binding
to DDR1 per se, rather than receptor clus-
tering, is responsible for the effect. Inter-
estingly, all of the antibodies bind to the
membrane proximal DS-like domain and,
surprisingly, they do not block binding of
collagen peptides. The inhibitory effect
of these antibodies on collagen-induced
DDR1 phosphorylation must therefore
occur through some indirect or steric
effect. A key question is what interactions
might be sterically blocked by antibody
binding to the DS-like domain? Unfortu-
nately the present study cannot provide
a complete answer to this question, but
several observations provide fuel for
speculation and, importantly, direction
for additional investigation.
Molecular mechanisms have been
proposed for two other inhibitory anti-
bodies that inhibit receptor function
through steric effects—the binding of efa-
lizumab to the lymphocyte function-asso-
ciated antigen 1 (LFA-1) (Li et al., 2009)
and the binding of matuzumab to the
epidermal growth factor receptor (EGFR)
(Schmiedel et al., 2008). The epitopes for
these antibodies do not overlap with the
ligand-binding sites on their cognate
receptors, but they are close by. WhenStructure 20, April 4, 2012bound to LFA-1, efalizumab sterically
impairs access of the ICAM-1 to its
binding site on the receptor (clashing
with regions of the ligand that are not
involved in binding). Matuzumab achieves
its inhibitory effect on EGFR by sterically
restricting the EGF-induced conforma-
tional changes in the receptor that are
required for ligand-induced dimerization.
The 3E9 antibody described by Carafoli
et al. (2012)—and all other seven inhibi-
tory antibodies studied—bind to the DS-
like domain, quite distant from the primary
collagen-binding site. It seems highly
unlikely that their inhibitory effects result
from steric restriction of collagen binding.
Rather, as suggested by Carafoli et al.
(2012), it seems likely that these anti-
bodies prevent the DDR1 dimer from
adopting the conformation required for
activation of the intracellular kinase
domains to exert their inhibitory effects.
Unfortunately, there is currently no
detailed information about the nature of
any DDR1 dimer, either in the absence
or presence of collagen. The extracellular
regions of DDRs are monomeric. Further,
in the intact receptor, the long, presumed
unstructured, extracellular JM regions
make it hard to predict how contacts
between the DS or DS-like domains could
be coupled to events inside the cell.
Although the soluble DDR1 protein is
monomeric in solution, the authors interro-
gate the relevanceof oneplausible crystal-
lographic dimer. Disruption of this dimer
interface does not abolish DDR1 activa-
tion. However, this analysis identifies a
conserved surface patch on the DS
domains that is essential for DDR1
signaling. Carafoli et al. (2012) offer two
possible roles for this conserved patch
that are illustrated in Figure 1B. In the first,
the conserved surface patch on the DS
domain contributes to essential inter-
receptor contacts in the DDR1 dimer. The
alternative, and favored (by the authors),
model is that this region represents
a second, lower affinity collagen-binding
site. In thismodel, collagen could crosslink
two receptor molecules to influence dimer
conformation. Further investigation is still
needed to resolve exactly how collagen
binding leads to activation of DDR1.ACKNOWLEDGMENTS
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Phosphorylation is a reversible post-translational modification that regulates many proteins and enzymes,
including proteases, as shown by two recent publications. Huang and colleagues and Vela´zquez-Delgado
and Hardy (this issue of Structure) describe how phosphorylation activates the protease activity of the
deubiquitinating enzyme DUBA and how it inhibits caspase-6, respectively.Post-translational protein modification
through phosphorylation is central to the
regulation of key cellular processes. The
human ‘‘kinome’’ (Manning et al., 2002;
http://kinase.com/human/kinome/), con-
sisting of at least 518 different kinases,
catalyzes millions of distinct phosphoryla-
tion events. Another well studies post-
translational event is proteolysis, which
is catalyzed by members of the human
‘‘degradome’’ (http://degradome.uniovi.
es/dindex.html). It is well appreciated
that so-called limited proteolysis, where
a specific protease cleaves a specific
substrate at one or several specific
sites, leading to its activation, deactiva-
tion, or subcellular relocation rather than
its complete degradation, is implicated
in many cellular events ranging from
cell division (Dephoure et al., 2008) to
apoptosis (Kurokawa and Kornbluth,
2009). Although the two events are fun-
damentally different—phosphorylation is
a reversible modification, whereas pro-
teolysis is irreversible—there is mounting
evidence that kinases and proteases
work hand-in-hand. For example, the
regulation of both cell proliferation and
apoptosis is dependent on the interplay
between protease and kinases (Lo´pez-Otı´n and Hunter, 2010). Caspase-3-
dependent processing and consequent
inactivation of the serine-threonine pro-
tein kinase AKT1 turns off survival path-
ways, whereas some deubiquitinating
proteases (DUBs) stabilize kinases by
removing ubiquitin tags from proteins
otherwise destined for degradation by
the ubiquitin-proteasome pathway. Like-
wise, phosphorylation is known to acti-
vate or inactivate proteases. Although it
is somehow easier to rationalize how
a proteolytic event leads to the activation
or inactivation of a functional protein, the
structural changes induced by phosphor-
ylation are more subtle. Two recent
papers provide exciting insight into how
phosphorylation can directly regulate
protease activity. While Huang et al.
(2012) provide a structural explanation of
how phosphorylation activates the deubi-
quitinating protease DUBA, Vela´zquez-
Delgado and Hardy (2012; this issue of
Structure) show that introducing a muta-
tion that mimics a biological phosphoryla-
tion event inactivates the apoptotic
protease caspase-6.
The deubiquitinating activity of human
deubiquitinase DUBA is strictly depen-
dent on the phosphorylation of Ser177by the casein kinase II (CK2). Indeed,
the ligand-free, unphosphorylated DUBA
rests in an inactive state, as the substrate
binding site is misaligned and parts of
the molecule appear to be highly mobile.
By itself, CK2 phosphorylation does not
induce any structural changes that would
be consistent with protease activation.
The active conformation is induced only
upon ubiquitin binding, as if the enzyme
‘‘folds around its substrate’’ (Huang
et al., 2012). The phosphate group stabi-
lizes the substrate-protease interaction
but does not directly interact with the
active site residues (Figure 1). It clamps
together two helices and appears in
turn to stabilize the core of the DUBA
structure and is involved in direct interac-
tions with C-terminal part of the ubiquitin
substrate.
Substrate-induced activation has pre-
viously been observed for other, structur-
ally diverse DUBs such as UCH-L3 and
USP7 (Hu et al., 2002; Johnston et al.,
1999). In their ligand free forms, these
enzymes exist in an inactive resting state.
Ubiquitin binding induces the maturation
of the otherwise obstructed and mis-
aligned substrate binding site and cata-
lytic center. This substrate-dependent
